Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Geneva, Switzerland, July 9, 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, today announced that it will lead a...
-
Geneva, Switzerland, 20 June 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders...
-
Geneva, Switzerland, May 28, 2019 – Addex Therapeutics (SIX: ADXN) announced today that its Annual General Meeting will take place on Wednesday, June 19, 2019, at 11:00am at the Campus Biotech, Chemin...
-
Geneva, Switzerland, May 20, 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, today announced that it has increased its...
-
Geneva, Switzerland, May 8, 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer will give...
-
Geneva, Switzerland, May 6, 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer will...
-
Robust cash position of CHF41.7 million providing runway through 2021Dipraglurant on track to start pivotal registration study in PD-LID by end of yearStrengthened team of clinical and preclinical...
-
Geneva, Switzerland, April 29, 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, today announced that it will report its...
-
Geneva, Switzerland, March 21, 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer and...
-
Geneva, Switzerland, 11 March 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that the company’s CEO,...